Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer [2] - The company is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [3] - Caris provides services in the U.S. and other international markets through its own operations and distributor partners [3] Financial Reporting - Caris Life Sciences will report its second quarter 2025 financial results on August 12, 2025 [1] - A conference call and live webcast will be held at 3:30 p.m. CT (4:30 p.m. ET) to discuss these financial results [1] - A replay of the webcast will be available shortly after the call on the Investor Relations section of the Caris Life Sciences website [1] Technological Capabilities - The company utilizes comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing, combined with advanced AI and machine learning algorithms [2] - Caris has developed a large-scale, multimodal clinico-genomic database and computing capability to analyze the molecular complexity of diseases [2] - This integration of next-generation sequencing, AI, machine learning technologies, and high-performance computing enables the development of advanced precision medicine diagnostic solutions [2]